Co-founder and CEO
Dr. Andreas Persidis is the CEO and one of the two co-founders of Biovista Inc. He is responsible for developing the vision and positioning of the company as a leader in the systematic drug repositioning and Augmented Intelligence space in the life sciences industry. He is also involved in all new product development work of Biovista, in forging strategic collaborations and in contributing to the evolution of the industry sectors of interest to the company.
Dr. Persidis is a member of the European Innovation council, an expert advisor to the European Commission and the Austrian government, has managed on behalf of the European Commission a roadmap study on systematic innovation, has advised the Hellenic government on innovation strategy and research priorities in the areas of IT and the life sciences and since 2010 is the President of the Hellenic BioCluster (HBio). Prior to Biovista, Dr. Persidis managed technology development teams at EU corporations in the engineering, software and telecoms fields.
He has published extensively in international journals and is an invited speaker at forums on drug repositioning, innovation and export oriented high-tech companies.
CEO at Catalia Health
Dr. Kidd is focused on innovating within the rapidly changing healthcare technology market. He is the founder and CEO of Catalia Health, a company that delivers patient engagement across a variety of chronic conditions. Catalia Health creates long-term engagement with patients in order to improve quality of care and deliver data and patient reported outcomes to pharma and providers. His experience lies in healthcare applications of new technologies, with expertise in developing simple interfaces to complex systems and the application of healthcare technologies to everyday life.
Following an extensive career with leadership roles for several global biosciences corporations, Michael Kowolenko, Ph.D., transferred his passion for data driven, strategic decision making to the classroom at the NC State Poole College of Management where he was named a Principle Research Scholar in Poole College’s Office of the Dean; an Industry Fellow of the Center for Innovation Management Studies, based in the college; and an IBM University Fellow.
While at NC State Michael co-founded Data Decision Models Inc., a big data analytics firm with a focus on the pharmaceutical industry. At Data Decision Models Michael helps customers make well informed business decisions through the use of predictive analytics to extract highly relevant knowledge from vast amounts of data. “It’s all about the question. The better the question, the better the answer”.
Senior Director of AI & Machine Learning
As the Senior Director of Artificial Intelligence and Machine Learning at BERG Analytics, Leonardo leads the analysis of internal and customers projects, the development of new analytical methodologies, and the maintenance and continuous improvement of BERG HPC platform.
He is know for efficient management of teams with various core competencies,
solid hands-on experience in both Biology and Data Analysis fields allowing for an effective execution of multi-fields projects.
He has a proven record of using data-driven approaches in the development/automation of ETL and data analysis pipelines
He also has extensive experience in applying AI & Machine Learning methodologies to derive actionable outputs from molecular, clinical and RWE data.
Agility Health Tech
Award-winning pharmaceutical scientist, strategist and innovator with >15 years’ experience in developing pharmaceutical products in global companies, virtual biotechs and contract research organisations (CROs). As both a strategic and technical leader, I have an exceptional track record of delivery. As Founder and Director of Agility Health Tech, I consult globally to healthcare and technology companies, ranging from spin-out to multinational companies, on how to fast track their technologies to market and help them to convey the benefits of their science through impactful communications. Key areas of expertise include pharmaceuticals, medical technologies, diagnostics, and “future health” sectors, primarily personalised and regenerative medicine, digital health and nanotechnology.
Dr. Eric Little
Eric is the Chief Data Officer working on the research & development of semantic technologies and their application to analytics, including graph-based computing, data modeling and advanced computational reasoning within pharmaceutical and biotech verticals. Working with pharma and biotech customers to design and implement new and cutting edge technologies for improved data management that can ultimately lead to new types of solutions and specialized analytics-based products. We are moving the conversation from Big Data to BIG ANALYSIS.
Ph.D. in Philosophy and Cognitive Science (2002). Post-Doctoral Fellowship in Industrial Engineering on multisource information fusion applications (2002-04).
Former Assistant Professor of Doctoral Studies in Health Policy & Education and Director of the Center for Ontology and Interdisciplinary Studies (COIS) at D’Youville College in Buffalo, NY.
Published in the areas of cognitive science, ontology, information fusion, electronic health records, and human factors engineering. Delivered lectures on ontology, philosophy, biomedicine, and cognitive science in Germany, Canada, Italy, United Kingdom and throughout the U.S.
Research has been supported by numerous government agencies such as AFOSR, ARL, ONR, MDA as well as several commercial clients including BP, JnJ, BCBS and others.
His Specialties includes Ontology design/implementation, data modeling, knowledge management, cognitive engineering, organizational theory, semantic enterprise architecture
Marcin von Grotthuss
Senior Computational Scientist
The Broad Institute
Credo: the properly conducted analysis of combined clinical, molecular and genomic data can be easily translated into clinical applications to increase a success rate of drug developments and to provide personalized medicine solution to patients.
Carolina Garcia Rizo
A global multilingual executive with an MBA and a Ph.D. in Physics/Chemistry, 15+ years of experience in Business Development and Healthcare strategy consulting, leading and executing commercial sales operations in Biotech and Molecular Diagnostics in the area of Immuno and Oncology. Leadership in Precision Medicine, CDx, Genomics, and Bioinformatics. Proven success in turnarounds, new markets expansion, and partnerships, driving sustainable growth and leading cross-functional teams worldwide. Fluent in German, Spanish, Portuguese and English. Conversational in French and Italian.
Industries: Biotechnology/ Healthcare/ Diagnostics/ MEdical Devices/ Bioinformatics/ AI/ Digital Health
Specialties: International Business Development. Commercial Operations. Growth and Innovation Strategy. Venture. M&A. Technology Scouting. Funding.
Emmanuel Fombu, MD, MBA
Physician, Healthcare, Futurist
Award Winning Author
Dr Fombu is a recognized authority on the convergence of digital technologies and healthcare. He is an award winning and best selling author, physician, Keynote speaker, investor, entrepreneur and medical futurist with over 10 years combined experience in clinical medicine, drug development, medical affairs, digital medicine, business development and licensing, research, pragmatic trials and product lifecycle management strategy in biopharmaceutical industry and private equity.
His current focus is on how digital technologies can be leveraged to better measure healthcare related product’s real world effectiveness and value, and also to design more comprehensive disease management systems in partnership with digital health startups, health systems, payers and providers.
In addition to his book, The Future of Healthcare: Human and Machine Partnering for Better Outcomes, Dr. Fombu has authored multiple research papers and abstracts in renowned peer reviewed journals. As a healthcare futurist and 2017 winner of the prestigious New York City Health Business Leaders Boldest Digital Health Influencer Award, Dr Fombu is a champion and advocate for value based healthcare, personalized medicine, mhealth, nanotechnology, big data, artificial intelligence, machine learning and digital medicine. He serves as an external advisory board member at the Massachusetts Institute of Technology’s MIT.nano project.
Dr Fombu did his clinical training at Emory-Crawford Long Hospital and holds an MBA from both Cornell University’s Johnson School of Business and Queen’s University’s Smith School of Business. He also earned a certification in Artificial Intelligence: Implications for Business Strategy from MIT’s Sloan school of management and Computer Science Artificial Intelligence Lab. He lives in New York City.
Joanne M. Hackett
Chief Commercial Officer
Accomplished entrepreneur, scientist and strategist with experience in the execution and management of complex business transactions. Current responsibilities include creating a portfolio of external investments and strategic alliances which advances technology and product strategies, creates a sustainable competitive advantage, and contributes to attainment of research, development and commercialisation goals. Broad business development experience includes the negotiation, execution and management of hundreds of transactions with Pharma, Biotech, academia and non-profits including co-development/co-promotion, in/out licensing, collaborative R&D, consortia. Highly skilled in manoeuvring and gaining consensus in a matrixed environment and leading cross functional teams charged with setting external investment strategies and the identification and evaluation of targets.
Ph. D. in Structural Biology
Specialties: Cell line cultivation and development Mammalian cell line expression Recombinant proteinexpression Flow cytometry Glycoform profiling Structural biology & X-Ray crystallography Proteinexpression systems & Protein science Protein crystallization Immunogenicity studies Virology